|Systematic (IUPAC) name|
|Molecular mass||578.59 g/mol|
Netupitant is an antiemitic drug. In the United States, the combination drug netupitant/palonosetron (Akynzeo) is approved by the Food and Drug Administration for prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy.
Mechanism of action
Netupitant is a selective NK1 receptor antagonist.
- "FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy".
- Rizzi A, Campi B, Camarda V, Molinari S, Cantoreggi S, Regoli D, Pietra C, Calo G (2012). "In vitro and in vivo pharmacological characterization of the novel NK(1) receptor selective antagonist netupitant". Peptides 37: 86–97.